![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Z-PROFILE: Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
B. Conway1, E. Tam2, J. Tremblay3, C. Fraser4, A. Ramji5, S. Borgia6, K. Tsoi7, E. Yoshida8, B. Rajendran9, K. Stewart10, G. Macphail11, B. Trottier12, P. Ghali13, J. Halsey-Brandt14 and J.B. Trepanier14 1 Vancouver Infectious Diseases Centre, BC, Canada; 2 LAIR Centre, BC, Canada; 3 Centre Sida Amitie, QC, Canada; 4 The Cool Aid Community Health Centre, BC, Canada; 5 GI Research Institute (GIRI), Gastroenterology Division, BC, Canada; 6 William Osler Health System, ON, Canada; 7 St. Joseph's Healthcare Hamilton, ON, Canada; 8 Vancouver General Hospital, BC, Canada; 9 The Peterborough Clinic, ON, Canada; 10 Saskatchewan Infectious Disease Care Network, SK, Canada; 11 Calgary Urban Project Society (CUPS), AB, Canada; 12 Clinique medicale du Quartier Latin, QC, Canada; 13 McGill University Health Center, QC, Canada; 14 Merck Canada Inc., Kirkland, QC, Canada.
![0417181](../images%20/041718/041718-5/0417181.gif)
![0417182](../images%20/041718/041718-5/0417182.gif)
![0417183](../images%20/041718/041718-5/0417183.gif)
![0417184](../images%20/041718/041718-5/0417184.gif)
![0417185](../images%20/041718/041718-5/0417185.gif)
![0417186](../images%20/041718/041718-5/0417186.gif)
![0417187](../images%20/041718/041718-5/0417187.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|